Avanos Change To Inventory vs Free Cash Flow Analysis

AVNS Stock

USD 19.16 0.02 0.10%

Avanos Medical financial indicator trend analysis is way more than just evaluating Avanos Medical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avanos Medical is a good investment. Please check the relationship between Avanos Medical Change To Inventory and its Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avanos Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Avanos Stock please use our How to Invest in Avanos Medical guide.

Change To Inventory vs Free Cash Flow

Change To Inventory vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avanos Medical Change To Inventory account and Free Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Avanos Medical's Change To Inventory and Free Cash Flow is 0.53. Overlapping area represents the amount of variation of Change To Inventory that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Avanos Medical, assuming nothing else is changed. The correlation between historical values of Avanos Medical's Change To Inventory and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Inventory of Avanos Medical are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Change To Inventory i.e., Avanos Medical's Change To Inventory and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Avanos Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avanos Medical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avanos Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Avanos Stock please use our How to Invest in Avanos Medical guide.At this time, Avanos Medical's Discontinued Operations is comparatively stable compared to the past year. Tax Provision is likely to gain to about 2.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 286.2 M in 2024.

	2021	2022	2024 (projected)
Interest Expense	3.3M	10M	16.1M
Depreciation And Amortization	38.3M	41.1M	43.0M

Interest Expense Depreciation And Amortization

Avanos Medical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Good Will	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets
Total Assets		0.81	0.93	0.91	0.42	0.0	-0.19	0.78	0.39	0.16	0.84	0.94	0.95	0.89	-0.22	-0.06	0.84	0.24	0.92	0.75	0.2	0.19	0.81	0.01	0.22	0.63
Other Current Liab	0.81		0.75	0.75	0.34	-0.36	-0.06	0.62	0.11	0.27	0.77	0.77	0.88	0.68	-0.06	-0.16	0.93	0.2	0.73	0.59	0.21	0.38	0.43	0.17	0.42	0.46
Total Current Liabilities	0.93	0.75		0.76	0.53	-0.11	-0.19	0.89	0.41	0.22	0.91	0.9	0.85	0.77	-0.21	-0.16	0.76	0.08	0.78	0.86	0.27	0.32	0.88	0.21	0.35	0.48
Total Stockholder Equity	0.91	0.75	0.76		0.2	0.06	-0.06	0.53	0.27	-0.02	0.68	0.81	0.92	0.84	-0.05	0.13	0.77	0.35	0.96	0.44	0.01	-0.08	0.64	-0.13	-0.03	0.68
Other Liab	0.42	0.34	0.53	0.2		0.1	-0.69	0.51	0.27	0.5	0.36	0.52	0.26	0.56	-0.67	0.01	0.38	0.37	0.38	0.67	0.93	0.6	0.55	-0.29	0.61	0.56
Net Tangible Assets	0.0	-0.36	-0.11	0.06	0.1		-0.55	-0.08	0.61	-0.31	-0.45	0.02	-0.2	0.35	-0.52	0.37	-0.38	0.26	0.21	-0.07	0.11	-0.4	0.28	-0.68	-0.4	0.46
Retained Earnings	-0.19	-0.06	-0.19	-0.06	-0.69	-0.55		-0.29	-0.46	-0.37	0.04	-0.36	0.02	-0.53	0.98	-0.41	-0.11	-0.13	-0.33	-0.42	-0.76	-0.5	-0.41	0.53	-0.5	-0.47
Accounts Payable	0.78	0.62	0.89	0.53	0.51	-0.08	-0.29		0.62	0.34	0.82	0.82	0.67	0.64	-0.35	-0.11	0.62	-0.07	0.6	0.9	0.28	0.49	0.85	0.3	0.48	0.29
Cash	0.39	0.11	0.41	0.27	0.27	0.61	-0.46	0.62		0.0	0.13	0.42	0.18	0.51	-0.49	0.2	0.02	0.1	0.38	0.47	0.12	0.0	0.64	-0.16	-0.02	0.41
Other Assets	0.16	0.27	0.22	-0.02	0.5	-0.31	-0.37	0.34	0.0		0.26	0.19	0.15	0.17	-0.4	-0.01	0.29	-0.14	0.1	0.4	0.57	0.67	0.08	0.11	0.67	0.17
Long Term Debt	0.84	0.77	0.91	0.68	0.36	-0.45	0.04	0.82	0.13	0.26		0.82	0.84	0.55	-0.01	-0.24	0.83	-0.05	0.64	0.78	0.13	0.43	0.69	0.45	0.45	0.21
Net Receivables	0.94	0.77	0.9	0.81	0.52	0.02	-0.36	0.82	0.42	0.19	0.82		0.87	0.88	-0.38	0.1	0.83	0.2	0.87	0.84	0.32	0.32	0.84	-0.03	0.34	0.58
Good Will	0.95	0.88	0.85	0.92	0.26	-0.2	0.02	0.67	0.18	0.15	0.84	0.87		0.78	-0.01	-0.08	0.92	0.21	0.87	0.62	0.05	0.15	0.62	0.09	0.19	0.53
Common Stock Total Equity	0.89	0.68	0.77	0.84	0.56	0.35	-0.53	0.64	0.51	0.17	0.55	0.88	0.78		-0.52	0.21	0.7	0.38	0.95	0.65	0.42	0.16	0.77	-0.39	0.19	0.83
Retained Earnings Total Equity	-0.22	-0.06	-0.21	-0.05	-0.67	-0.52	0.98	-0.35	-0.49	-0.4	-0.01	-0.38	-0.01	-0.52		-0.31	-0.14	-0.08	-0.33	-0.46	-0.72	-0.55	-0.43	0.44	-0.55	-0.43
Common Stock Shares Outstanding	-0.06	-0.16	-0.16	0.13	0.01	0.37	-0.41	-0.11	0.2	-0.01	-0.24	0.1	-0.08	0.21	-0.31		-0.11	0.08	0.2	-0.1	0.1	-0.16	0.09	-0.59	-0.14	0.23
Inventory	0.84	0.93	0.76	0.77	0.38	-0.38	-0.11	0.62	0.02	0.29	0.83	0.83	0.92	0.7	-0.14	-0.11		0.2	0.77	0.63	0.24	0.45	0.46	0.13	0.49	0.42
Other Current Assets	0.24	0.2	0.08	0.35	0.37	0.26	-0.13	-0.07	0.1	-0.14	-0.05	0.2	0.21	0.38	-0.08	0.08	0.2		0.37	-0.04	0.37	-0.21	0.1	-0.6	-0.19	0.71
Other Stockholder Equity	0.92	0.73	0.78	0.96	0.38	0.21	-0.33	0.6	0.38	0.1	0.64	0.87	0.87	0.95	-0.33	0.2	0.77	0.37		0.54	0.23	0.08	0.72	-0.26	0.12	0.78
Total Liab	0.75	0.59	0.86	0.44	0.67	-0.07	-0.42	0.9	0.47	0.4	0.78	0.84	0.62	0.65	-0.46	-0.1	0.63	-0.04	0.54		0.47	0.55	0.82	0.16	0.54	0.33
Deferred Long Term Liab	0.2	0.21	0.27	0.01	0.93	0.11	-0.76	0.28	0.12	0.57	0.13	0.32	0.05	0.42	-0.72	0.1	0.24	0.37	0.23	0.47		0.62	0.31	-0.41	0.62	0.5
Short Long Term Debt	0.19	0.38	0.32	-0.08	0.6	-0.4	-0.5	0.49	0.0	0.67	0.43	0.32	0.15	0.16	-0.55	-0.16	0.45	-0.21	0.08	0.55	0.62		0.18	0.28	1.0	-0.08
Total Current Assets	0.81	0.43	0.88	0.64	0.55	0.28	-0.41	0.85	0.64	0.08	0.69	0.84	0.62	0.77	-0.43	0.09	0.46	0.1	0.72	0.82	0.31	0.18		-0.02	0.19	0.52
Treasury Stock	0.01	0.17	0.21	-0.13	-0.29	-0.68	0.53	0.3	-0.16	0.11	0.45	-0.03	0.09	-0.39	0.44	-0.59	0.13	-0.6	-0.26	0.16	-0.41	0.28	-0.02		0.27	-0.62
Short Term Debt	0.22	0.42	0.35	-0.03	0.61	-0.4	-0.5	0.48	-0.02	0.67	0.45	0.34	0.19	0.19	-0.55	-0.14	0.49	-0.19	0.12	0.54	0.62	1.0	0.19	0.27		-0.04
Intangible Assets	0.63	0.46	0.48	0.68	0.56	0.46	-0.47	0.29	0.41	0.17	0.21	0.58	0.53	0.83	-0.43	0.23	0.42	0.71	0.78	0.33	0.5	-0.08	0.52	-0.62	-0.04

Click cells to compare fundamentals

Avanos Medical Account Relationship Matchups

Avanos Medical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	1.7B	1.6B	1.8B	1.7B	1.5B
Other Current Liab	114.8M	65M	50.4M	83.7M	127.4M	83.8M
Total Current Liabilities	212.5M	166.3M	139.2M	185.8M	234.6M	200.5M
Total Stockholder Equity	1.3B	1.3B	1.3B	1.3B	1.2B	1.4B
Other Liab	11.2M	16.7M	18.7M	48.9M	56.2M	30.6M
Net Tangible Assets	280M	296.3M	321.1M	220.8M	253.9M	181.9M
Retained Earnings	(288.3M)	(315.5M)	(310.3M)	(253.1M)	(314.9M)	(330.6M)
Accounts Payable	83M	67.6M	56.4M	67.9M	56.3M	86.0M
Cash	205.3M	111.5M	118.5M	127.7M	87.7M	147.2M
Other Assets	27.4M	71M	26.5M	22.2M	25.5M	24.3M
Long Term Debt	248.1M	180M	130M	226.3M	159.4M	256.1M
Net Receivables	150.5M	163.8M	167.9M	118.2M	142.8M	181.9M
Good Will	800.9M	802.5M	801.6M	819.4M	796.1M	728.2M
Retained Earnings Total Equity	(288.3M)	(315.5M)	(310.3M)	(253.1M)	(227.8M)	(239.2M)
Common Stock Shares Outstanding	47.6M	47.8M	48.6M	47.3M	46.6M	51.7M
Inventory	145.9M	168.9M	150.3M	190.3M	163.2M	152.4M
Other Current Assets	23.5M	18.9M	31.6M	196.2M	93.3M	50.8M
Other Stockholder Equity	1.6B	1.6B	1.6B	1.6B	1.6B	1.7B
Total Liab	534.4M	416.3M	330.7M	495.7M	456.1M	466.7M
Total Current Assets	538.5M	467.2M	418.6M	499.8M	487M	627.7M
Accumulated Other Comprehensive Income	(32M)	(28.1M)	(33.8M)	(35.8M)	(27M)	(28.4M)
Treasury Stock	(5.3M)	(8.9M)	(9.8M)	(21.3M)	(19.2M)	(18.2M)
Intangible Assets	168.2M	184.3M	157.7M	251M	239.5M	166.7M
Property Plant Equipment	184.5M	175.3M	168.1M	163.9M	147.5M	161.6M
Short Long Term Debt Total	325.4M	248.8M	187.5M	280M	209.1M	264.0M
Property Plant And Equipment Net	248.5M	223.6M	206.7M	194.5M	144M	183.3M
Net Debt	120.1M	137.3M	69M	152.3M	121.4M	148.1M
Non Current Assets Total	1.3B	1.2B	1.2B	1.3B	1.2B	1.1B
Non Currrent Assets Other	11.3M	11.8M	16.5M	17.6M	19.3M	12.0M
Cash And Short Term Investments	205.3M	111.5M	118.5M	127.7M	87.7M	159.4M
Liabilities And Stockholders Equity	1.8B	1.7B	1.6B	1.8B	1.7B	1.6B
Non Current Liabilities Total	321.9M	250M	191.5M	309.9M	221.5M	288.4M
Property Plant And Equipment Gross	248.5M	223.6M	206.7M	194.5M	266.9M	191.5M
Long Term Debt Total	248.1M	180M	130M	226.3M	203.7M	273.0M
Capital Surpluse	1.6B	1.6B	1.6B	1.6B	1.9B	1.7B
Non Current Liabilities Other	73.8M	64.3M	51.9M	18.7M	4.1M	3.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Avanos Stock Analysis

When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC